Rituximab shows second-line promise in autoimmune limbic encephalitis

“Rituximab is effective and safe as a second-line immunotherapy for autoimmune limbic encephalitis, regardless of autoantibody status. Additional monthly rituximab therapy might potentiate the efficacy of rituximab,” concludes the authors of this Rituximab study published in medical journal, Neurology. 

Lucy Piper of News Medical, an online, open-access medical information provider has published the article”Rituximab shows second-line promise in autoimmune limbic encephalitis” synthesizing the details of the study.